A simulation framework based on pooled trial data indicates that an average annual sudden cardiac death risk of 3 percent—equivalent to approximately 12 percent over five years—represents the lowest practical threshold for implantable cardioverter-defibrillator therapy to produce a clinically meaningful mortality benefit. This finding directly addresses a critical gap in clinical cardiology, where no prior consensus existed regarding the risk threshold of sudden cardiac death required for the practical design, evaluation of prediction models, and treatment decisions surrounding implantable cardioverter-defibrillators. Under typical clinical conditions involving competing non-sudden causes of death, populations experiencing an average annual risk of 3 percent or higher were identified as the groups most likely to derive a clear survival benefit from device therapy.
To determine the minimal average risk threshold capable of translating into a measurable reduction in mortality, researchers established baseline simulation assumptions derived from 18 previous randomized controlled trials. A primary objective of the modeling design was evaluating the degree to which competing non-sudden mortality influences the real-world survival benefit delivered by implantable cardioverter-defibrillators.
The research team employed an inverse-variance weighted meta-analysis of the 18 included randomized controlled trials to estimate the overall efficacy of implantable cardioverter-defibrillators and provide input parameters for the simulations. From this meta-analytic synthesis, the efficacy of implantable cardioverter-defibrillators in reducing sudden cardiac deaths or similar life-threatening arrhythmic events was estimated at 56 percent, with an uncertainty range spanning from 48 percent to 62 percent. Additionally, the meta-analysis established a pooled estimate of 5 percent for annual non-sudden mortality across the trial populations, providing a standardized benchmark for competing risk in the primary simulation models.
Clinical relevance within the study was formally defined as achieving a number needed to treat of 20 or fewer across designated evaluation windows of 5-year and 10-year time horizons. In conducting correlation analysis across the trial datasets, the researchers confirmed that the average annual incidence of sudden cardiac death within trial populations served as the key factor associating with the overall effectiveness of device therapy in reducing mortality. This association was statistically confirmed through a strong positive correlation, yielding a Pearson correlation coefficient of r = 0.653 with a significance level of p < 0.01, demonstrating that underlying baseline incidence is central to therapy success.
In the primary simulation incorporating the pooled 5 percent annual non-sudden mortality rate and device efficacy between 48 percent and 62 percent, the 3 percent average annual risk threshold held firm even after explicitly controlling for excess overlapping mortality among individuals successfully saved from sudden cardiac death by an implantable cardioverter-defibrillator. This adjustment ensured that the projected clinical benefit remained valid despite post-event mortality risks among treated patients. The simulation demonstrated that under conditions of substantial competing non-sudden mortality, maintaining at least a 3 percent annual sudden death risk is necessary to achieve clinically relevant reductions in overall patient mortality.
The modeling framework also examined alternative demographic conditions, revealing that risk thresholds depend heavily on the background rate of non-sudden death. In specific populations characterized by a very low annual incidence of non-sudden mortality of 1 percent, the lowest practical threshold decreased to an average annual risk of 1.3 percent evaluated over an extended 10-year time horizon, under the assumption of no overlapping mortality. Consequently, the investigators concluded that while populations with an average annual incidence of 3 percent or higher most likely benefit from implantable cardioverter-defibrillator therapy even under substantial competing risk, lower risk thresholds should only be considered in populations exhibiting very low rates of non-sudden mortality.
Subject of Research: Clinical risk thresholds for sudden cardiac death prevention
Article Title: Defining clinically relevant risk threshold for predicting sudden cardiac death
Article References: Hernesniemi, J., Ahola, R., & Uimonen, M. (2026). Defining clinically relevant risk threshold for predicting sudden cardiac death. Scientific Reports. https://doi.org/10.1038/s41598-026-78332-5
Image Credits: AI Generated
DOI: 10.1038/s41598-026-78332-5
Keywords: sudden cardiac death, implantable cardioverter-defibrillators, risk threshold, mortality benefit, competing risk, cardiovascular simulations, meta-analysis, number needed to treat, Defining, clinically, relevant, risk
Cite Scienmag News
Scienmag. (November 9, 2026). Simulation Identifies Clinically Relevant Risk Threshold for Sudden Cardiac Death Intervention. https://scienmag.com/simulation-identifies-clinically-relevant-risk-threshold-for-sudden-cardiac-death-intervention/
Scienmag. "Simulation Identifies Clinically Relevant Risk Threshold for Sudden Cardiac Death Intervention." Scienmag, 9 November 2026, https://scienmag.com/simulation-identifies-clinically-relevant-risk-threshold-for-sudden-cardiac-death-intervention/. Accessed 22 November 2026.
Scienmag. "Simulation Identifies Clinically Relevant Risk Threshold for Sudden Cardiac Death Intervention." Scienmag. November 9, 2026. https://scienmag.com/simulation-identifies-clinically-relevant-risk-threshold-for-sudden-cardiac-death-intervention/








